Dermatology Studies Open For Patient Referral

Birmingham, Alabama

Total Skin and Beauty Dermatology Center - For more info or to refer a patient for evaluation and enrollment, Call 205-933-0987 for Angela, ext 168 or Brittany, ext 136.

• Palmoplantar Pustulosis: ages 19 – 75, moderate to severe PPP, PPPASI ? 12 and PPPGA ? 3, at least 30% on 2 palmoplantar surfaces or 60% on one, pustules/vesicles on at least one palm or sole ? 2, possible placebo
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis.

• Alopecia Areata: ages 19 – 75, ? 50% hair loss, subcutaneous injections, possible placebo
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects with Alopecia Areata

• Plaque Psoriasis - Humira Biosimilar: ages 19 – 75, no placebo, PASI ? 12, ? 10% BSA and sPGA ? 3
A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With Continued Use of Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis

• Plaque Psoriasis – KoBioLabs Microbiome: ages 19 – 75, PASI 5-15, BSA 5-15%, severity moderate or marked, stool collections are required
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis.

• Plaque Psoriasis – Nimbus Oral TYK2: ages 19 – 70, 5 treatment arms, possible placebo, PASI ? 12, ? 10% BSA and sPGA ? 3
A phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety and tolerability of NDI-034858 in subjects with moderate to severe plaque psoriasis.

• Galderma Acne Scar: ages 19 – 75, IGA of 3 or 4, 20 inflammatory lesions, minimum of 10 acne scars, Split Face Treatment so half treated/half placebo, at home video dosing diary required
Evaluation of the Risk of Atrophic Acne Scar Formation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 µg/g cream versus vehicle cream over 24 weeks.

Soon to be open for enrollment:
• Novartis Hives: ages 19+, possible placebo, oral medication
A Multicenter, Randomized, Double- Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (LOU064) To Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria Patients Inadequately Controlled By H1- Antihistamines.

• Leo Tralo Autoinjector for AD: ages 12+, no placebo
An open-label, single-arm, phase 3 trial to evaluate the efficacy and safety of tralokinumab administered by an autoinjector in subjects with moderate-to-severe atopic dermatitis

• Castle Identity Registry:
Inflammatory Skin Disease Treatment Identification Study (IDENTITY) - To identify a gene expression and/or mutational profile that can guide treatment selection in patients with AD, psoriasis, and related conditions.

Registries always open for enrollment:
• Corrona (Corevitas) AD - Atopic Dermatitis Registry: A Study of Post-Approval Drug Safety and Effectiveness
• Corrona (Corevitas) PSO - A Prospective, Non-Interventional, Research Study To Prospectively Study the Natural History Of Psoriasis, The Prevalence And Incidence of Comorbidities, and Targeted Adverse Events, As Well As The Utilization Patterns And The Comparative Effectiveness and Comparative Safety of Approved Psoriasis Treatments For Patients With Psoriasis Under the Care Of A Dermatologist
• Psolar - A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
• LITE - A pragmatic trial of home versus office based narrow band ultraviolet B phototherapy for the treatment of psoriasis.